Max Chat
Calendrier des promotions Lumos Pharma, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Lumos Pharma, Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.Paramètres de base
IPO date
2011-11-11
ISIN
US55028X1090
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 12.07 | 1 |
| P/BV | 0.9068 | 9 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -83.75 | 0 |
| ROE | -124.64 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.1801 | 10 |
| Debt/Ratio | 0.162 | 10 |
| Debt/Equity | 0.4883 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 119.12 | 10 |
| Rentabilité Ebitda, % | -14.76 | 0 |
| Rentabilité EPS, % | -87.34 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 4.34 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 4.34 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.30d | 4.34 $ | 4.34 $ | 4.34 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.90d | 4.34 $ | 4.34 $ | 4.34 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.180d | 4.34 $ | 4.34 $ | 4.34 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.1y | 3.9 $ | 1.45 $ | 4.45 $ | +11.28 % | 0 % | 0 % |
| common.calendar.number_days.3y | 8.57 $ | 1.45 $ | 9.52 $ | -49.36 % | 0 % | 0 % |
| common.calendar.number_days.5y | 13.8 $ | 1.45 $ | 35.91 $ | -68.55 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.89 $ | 0.89 $ | 55.01 $ | +487.64 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 4.34 $ | 4.34 $ | 4.34 $ | 0 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Richard J. Hawkins | Founder, CEO & Chairman | 854.35k | 1949 (76 années) |
| Dr. John C. McKew Ph.D. | Chief Scientific Officer & President | 860.38k | 1964 (61 année) |
| Ms. Lori D. Lawley CPA | CFO & Principal Accounting Officer | 538.23k | 1984 (41 année) |
| Mr. Bradley J. Powers J.D. | Chief Compliance Officer & General Counsel | 677.08k | 1979 (46 années) |
| Mr. Aaron Schuchart B.B.A., CPA, M.B.A. | Chief Business Officer | N/A | 1966 (59 années) |
| Dr. Pisit Pitukcheewanont FAAP, M.D. | Chief Medical Officer | N/A | |
| Mr. Eddie L. Varnado M.B.A. | Corporate Controller | N/A | |
| Ms. Lisa Wells Miller | Senior Director of Investor Relations | N/A | |
| Ms. Alpa Parikh | Senior Vice President of CMC & Supply Management |
Informations sur l'entreprise
Adresse: United States, Austin. TX, 4200 Marathon Boulevard - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://lumos-pharma.com
Site web: https://lumos-pharma.com
